News
Hosted on MSN19d
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2025 Earnings Call TranscriptPacific Biosciences ... in long-read sequencing, continued momentum in the adoption of HiFi, and a robust innovation map. We are also committed to our plan of turning cash flow positive as we ...
Todd Friedman; Senior Director of Investor Relations; Pacific Biosciences of California Inc Christian Henry; President, Chief Executive Officer, Director; Pacific Biosciences of California Inc Jim ...
About Pacific Biosciences of California Inc. Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis.
Pacific Biosciences ... to reach positive cash flow by the end of 2027.” The company says it will focus on three key priorities: Accelerating the adoption of HiFi sequencing, Investing in ...
What Happened: Pacific Biosciences of California Inc. PACB ... training costs enable breakthroughs in gene editing and genome sequencing. Despite market headwinds like high interest rates ...
A bridge amplification step is performed to create a cluster of fragments with the same sequence. One strand of DNA is removed and fluorescently labeled nucleotides are passed by each cluster. An ...
The growth in consumable revenue in EMEA was driven by new customers scaling long-read sequencing during the ... So it uses, you know, the 25M flow cell, or smart cell as the principal tool ...
Pacific Biosciences' SMRT sequencing has higher error rates (or so the perception goes) than Illumina's, which has an impact on cost and time efficiency. Despite ...
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Trailmaker™, its user-friendly cloud platform purpose-built ...
And Pacific Biosciences recently laid off nearly 200 ... a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world.
Genome sequencing company Pacific Biosciences, a competitor of Illumina, is shutting down its San Diego location, laying off nearly 200 workers and downsizing its research pipeline to save about $ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results